ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT

Cardiovascular Research

Volumn 73, Issue 1, 2007, Pages 237-246

  Ceconi, Claudio ^a   Fox, Kim M ^b   Remme, William J ^c   Simoons, Marteen L ^d   Bertrand, Michael ^e   Parrinello, Giovanni ^f   Kluft, Cornelius ^g   Blann, Andrew ^h   Cokkinos, Dennis ⁱ   Ferrari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c Cardiovascular Research Foundation   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF BRESCIA   (Italy)

^g TNO   (Netherlands)

^h UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

ⁱ ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Endothelial function; Inhibition; Perindopril; von Willebrand factor

Indexed keywords

ANGIOTENSIN II; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICATIBANT; NITRATE; NITRITE; PERINDOPRIL; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADULT; ANGIOTENSIN BLOOD LEVEL; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CELL FUNCTION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; UMBILICAL VEIN; UPREGULATION;

EID: 33845587363     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.10.021     Document Type: Article

References (34)

1. The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA). Lancet 362 (2003) 782-788
2. Schwartzkopff B., Brehm M., Mundhenke M., and Strauer B.E. Prevention of accelerated atherosclerosis by normalization of resistance arteries in CAD patients: repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 36 (2000) 220-225
3. Levy B.I., Duriez M., and Samuel J.L. Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens 14 (2001) 7-13
4. Simoons M.L., Vos J., de Feyter P.J., Bots M.L., Remme W.J., Grobbee D.E., et al. EUROPA substudies, confirmation of pathophysiological concepts. Eur Heart J 19 (1998) J56-J60 [Suppl J]
5. Bots M.L., et al., on behalf of the EUROPA-PERFECT Investigators. PERindopril-Function of the Endothelium in Coronary artery disease Trial: the PERFECT study-substudy of EUROPA: rationale and design. Cardiovasc Drugs Ther 16 (2002) 227-236
6. Daly C.A., et al., on behalf of the EUROPA investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study, results from the PERSUADE substudy. Eur Heart J 26 (2005) 1369-1378
7. Scientific Committee of the PERTINENT Sub-Study. PERTINENT-PERindopril-Thrombosis, InflammatioN, Endothelial Dysfunction and Neurohormonal Activation Trial: a Sub-Study of the EUROPA Study. Cardiovasc Drugs Ther 17 (2003) 83-91
8. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., and van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332 10 (Mar 9 1995) 635-641
9. Bachetti T., Comini L., Pasini E., Cargnoni A., Curello S., and Ferrari R. ACE-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. J Mol Cell Cardiol 33 3 (2001) 395-403
10. Hermann K., Lang R.E., Unger T., Bayer C., and Ganten D. Combined high-performance liquid chromatography for the characterization and quantitative measurement of neuropeptides. J Chromatogr 312 (1984) 273-284
11. Campbell D.J., Kladis A., and Duncan A.M. Bradykinin peptides in kidney, blood, and other tissue of the rat. Hypertension 21 (1993) 155-165
12. Cargnoni A., Comini L., Bernocchi P., Bachetti T., Ceconi C., Curello S., et al. Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. Br J Pharmacol 133 (2001) 145-153
13. Jaffe E.A., Nachman R.L., Becker C.G., and Minick C.R. Culture of human endothelial cells derived from umbilical veins. J Clin Invest 52 (1973) 2745-2756
14. Agnoletti L., Curello S., Bachetti T., Malacarne F., Gaia G., Comini L., et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic. Role of tumor necrosis factor-α. Circulation 100 (1999) 1983-1991
15. Bachetti T., Comini L., Curello S., Bastianon D., Palmieri M., Bresciani G., et al. Co-expression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cells. J Mol Cell Cardiol 37 (2004) 939-945
16. Pfeffer M.A., et al., for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327 (1992) 669-677
17. Acute Infarction Ramipril Efficacy (AIRE) Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
18. Kober L., et al., for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
19. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med 316 (1987) 1429-1435
20. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
21. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
22. Vischer U.M., Emeis J.J., Bilo H.J., Stehouwer C.D., Thomsen C., Rasmussen O., et al. von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII). Thromb Haemost 80 (1998) 1002-1007
23. Valgimigli M., Agnoletti L., Curello S., Comini L., Francolini G., Mastrorilli F., et al. Serum from patients with acute coronary syndromes displays a pro-apoptotic effect on human endothelial cells. A possible link to pan-coronary syndrome. Circulation 107 (2003) 274-280
24. Tomiyama H., Motobe K., Zaydun G., Koji Y., Yambe M., Arai T., et al. Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan. Am J Hypertens 18 2 Pt 1 (2005) 178-182
25. Choy J.C., Granville D.J., Hunt D.W., and McManus B.M. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 33 (2001) 1673-1680
26. Kono Y., Sawada S., Kawahara T., Tsuda Y., Higaki T., Yamasaki S., et al. Bradykinin inhibits serum-depletion-induced apoptosis of human vascular endothelial cells by inducing nitric oxide via calcium ion kinetics. J Cardiovasc Pharmacol 39 (2002) 251-261
27. Zhuo J.L., Mendelsohn F.A., and Ohishi M. Perindopril alters vascular Angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary artery disease. Hypertension 39 (2002) 634-638
28. Todd P.A., and Fitton A. Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 42 1 (1991) 90-114
29. Sigurdsson A., Amtorp O., Gundersen T., Nilsson B., Remes J., and Swedberg K. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. Br Heart J 72 5 (1994) 422-427
30. Eriksson S.V., Eneroth P., Kjekshus J., Offstad J., and Swedberg K. Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Clin Cardiol 17 11 (1994) 603-606
31. Varin R., Mulder P., Tamion F., Richard V., Henry J.P., Lallemand F., et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 102 (2000) 351-356
32. Remme W.J. Prevention of cardiovascular events by perindopril in patients with stable coronary artery disease does not depend on blood pressure and its reduction-results from the EUROPA study. Circulation 110 (2004) III-628 [Abstract 2919]
33. Poole-Wilson P.A., et al., A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 364 9437 (2004) 849-857
34. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068